Option chain shows key data for Cadrenal Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cadrenal Therapeutics.

Cadrenal Therapeutics (NASDAQ:CVKD) Stock, Option Chain

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLT

BGNE

CNEY

CSBR

CVKD

FTCI

IBRX

ISPC

NITO

NTGR

PEGY

PMNT

PTIX

RYDE

SMFL

SYRA

TBIO

Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ACLS

APPS

ASTS

BETS

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BTDR

CAMP

CCTG

DYNT

EVER

GPRO

HCTI

HKIT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

LITE

LSPD

MGRX

MLGO

MLYS

MPWR

MRDB

NVST

OSCR

PBAX

PYPL

QNST

ROMA

TENX

THMO

TRUG

UCAR

VKTX

WETG

WIMI

YTEN

ZCMD

Shares of  Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ATRA

BCEL

BIOR

CANO

CHEA

DCFC

FDMT

GRDI

MEGL

NEXI

NSTG

TWOU

WORX

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading.

4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability &amp; clinical activity in wet AMD.

Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

Oppenheimer analyst Leland Gershell reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $646 to $675.

Price Target

Reiteration

Analyst Ratings

ARGX

Oppenheimer Reiterates Outperform on argenx, Raises Price Target to $675

RBC Capital analyst Matthew Hedberg reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and maintains $450 price target.

PANW

RBC Capital Reiterates Outperform on Palo Alto Networks, Maintains $450 Price Target

Offering Advertisers Enhanced Reach And Targeting Across Xumo Properties With PubMatic's Supply Path Optimization Capabilities

PUBM

Xumo Partners With PubMatic To Expand Programmatic Advertising

Oppenheimer analyst Ittai Kidron maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and maintains $180 price target.

SNOW

Oppenheimer Maintains Outperform on Snowflake, Maintains $180 Price Target

<a href="https://www.capitoltrades.com/issuers/435690" title="https://www.capitoltrades.com/issuers/435690">https://www.capitoltrades.com/issuers/435690</a>

Politics

General

VSAT

Watcing ViaSat; Traders Circulate Representative Debbie Wasserman Schultz Has Bought Stock In The Company

Financial giants have made a conspicuous bullish move on Super Micro Computer. Our analysis of options history for Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $2,286,540, and 9 were calls, valued at $866,659.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $24.0 and $75.0 for Super Micro Computer, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Super Micro Computer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Super Micro Computer's substantial trades, within a strike price spectrum from $24.0 to $75.0 over the preceding 30 days.
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201572_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.3</td>
<td>$48.1</td>
<td>$48.8</td>
<td>$75.00</td>
<td>$1.4M</td>
<td>551</td>
<td>298</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$29.95</td>
<td>$28.6</td>
<td>$29.25</td>
<td>$53.00</td>
<td>$731.2K</td>
<td>1.4K</td>
<td>250</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.45</td>
<td>$3.3</td>
<td>$3.45</td>
<td>$30.00</td>
<td>$312.3K</td>
<td>12.8K</td>
<td>455</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$24.00</td>
<td>$205.4K</td>
<td>2.6K</td>
<td>335</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$35.00</td>
<td>$115.0K</td>
<td>5.2K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
In light of the recent options history for Super Micro Computer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Super Micro Computer's Current Market Status</h3>
<ul>
<li>With a volume of 21,385,693, the price of SMCI is up 7.98% at $27.86. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Super Micro Computer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

SMCI

Smart Money Is Betting Big In SMCI Options

Investors with a lot of money to spend have taken a bullish stance on Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BAC, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Bank of America.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $27,620, and 7, calls, for a total amount of $677,470.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $48.0 for Bank of America, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Bank of America stands at 10933.33, with a total volume reaching 15,601.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bank of America, situated within the strike price corridor from $45.0 to $48.0, throughout the last 30 days.
<h3>Bank of America Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201567_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.56</td>
<td>$0.54</td>
<td>$0.55</td>
<td>$48.00</td>
<td>$183.2K</td>
<td>12.5K</td>
<td>4.8K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.96</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$47.00</td>
<td>$142.5K</td>
<td>26.4K</td>
<td>3.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.96</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$47.00</td>
<td>$95.0K</td>
<td>26.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.66</td>
<td>$1.63</td>
<td>$1.65</td>
<td>$47.00</td>
<td>$82.5K</td>
<td>23.2K</td>
<td>506</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.51</td>
<td>$0.5</td>
<td>$0.51</td>
<td>$48.00</td>
<td>$77.2K</td>
<td>12.5K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
In light of the recent options history for Bank of America, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Bank of America's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,855,697, the price of BAC is up by 1.17%, reaching $46.6.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>What The Experts Say On Bank of America</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $55.333333333333336.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $56. 
&#x2A; An analyst from Citigroup upgraded its action to Buy with a price target of $54. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Bank of America, maintaining a target price of $56. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Bank of America Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSTR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 348 extraordinary options activities for MicroStrategy. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 41% bearish. Among these notable options, 68 are puts, totaling $8,017,465, and 280 are calls, amounting to $41,504,526.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $69.0 to $990.0 for MicroStrategy over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for MicroStrategy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MicroStrategy's whale activity within a strike price range from $69.0 to $990.0 in the last 30 days. 
<h3>MicroStrategy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201562_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$261.0</td>
<td>$237.45</td>
<td>$253.92</td>
<td>$760.00</td>
<td>$1.3M</td>
<td>980</td>
<td align="right">257</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$215.15</td>
<td>$198.5</td>
<td>$202.92</td>
<td>$890.00</td>
<td>$1.1M</td>
<td>1.1K</td>
<td align="right">270</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$43.8</td>
<td>$41.5</td>
<td>$43.8</td>
<td>$472.50</td>
<td>$701.6K</td>
<td>322</td>
<td align="right">210</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$44.65</td>
<td>$39.85</td>
<td>$39.65</td>
<td>$475.00</td>
<td>$669.9K</td>
<td>567</td>
<td align="right">336</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$123.0</td>
<td>$113.2</td>
<td>$116.0</td>
<td>$600.00</td>
<td>$425.4K</td>
<td>1.1K</td>
<td align="right">263</td>
</tr>
</tbody>
</table>

<h3>About MicroStrategy</h3>
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.
After a thorough review of the options trading surrounding MicroStrategy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of MicroStrategy</h3>
<ul>
<li>Trading volume stands at 15,686,064, with MSTR's price up by 11.48%, positioned at $528.22.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About MicroStrategy</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $349.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for MicroStrategy, targeting a price of $300. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on MicroStrategy, maintaining a target price of $300. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for MicroStrategy, targeting a price of $275. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for MicroStrategy, targeting a price of $300. 
&#x2A; Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for MicroStrategy, targeting a price of $570. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MSTR

Check Out What Whales Are Doing With MSTR

Oppenheimer analyst Brian Schwartz reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and raises the price target from $330 to $385.

Oppenheimer Reiterates Outperform on Salesforce, Raises Price Target to $385

Quantum-Si Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares tanked over <a href="https://www.benzinga.com/general/health-care/24/11/42091430/nvidia-partners-with-quantum-si-to-advance-single-molecule-analysis">12.8% Thursday morning</a>.
The company plans to introduce Platinum Pro, an advanced version of its Platinum platform, in the first half of 2025. Platinum Pro will feature a streamlined workflow, reducing hands-on time and speeding up processing.
It will support both local and cloud-based data analysis, and introduce a &#8216;Pro Mode&#8217; for custom application development, offering a valuable tool for biopharmaceutical clients.
On the other hand, Quantum-Si will launch Proteus in the second half of 2026.
Proteus is expected to offer advanced capabilities, including ultrasensitive detection of proteoforms, unbiased analysis of complex samples, and a new rapid sequencing chemistry that reduces run time to 90 minutes or less.
The company expects Proteus to serve as the foundational platform for scaling sequencing output, progressing from tens of millions of reads per sample at launch to billions over time.
CEO Jeff Hawkins expects Proteus to &#8220;open broad new markets for diverse applications in protein analysis, driving increased revenue growth that will create significant value for our shareholders.&#8221;
&#8221;With these technology advancements and partnerships in place, we believe we will be able to further extend our leadership position in next-generation protein sequencing while also extending into other areas of proteomics more generally.&#8221;
To accelerate the development of Proteus and mitigate risks in the hardware platform delivery, Quantum-Si recently announced new partnerships and collaborations.
Yesterday, Quantum-Si announced a collaboration with Nvidia to develop its new proteomics platform.
Also, the company entered into a distribution agreement with Avantor, as per which, Avantor will distribute Quantum-Si&#8217;s Next-Generation Protein Sequencing (NGPS) portfolio in the U.S. and Canada, offering researchers across various market segments easier access t<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42085520/avantor-to-distribute-quantum-sis-next-generation-protein-sequencing-technology" rel="noreferrer noopener">o these innovative proteomics solutions</a>.
Price Action: Quantum-Si shares are down 12.88% at last check Thursday, trading around $1.21 a share. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42107830" target="_blank" rel="noreferrer noopener">Uber Could Pick Up $10M Stake In Chinese Autonomous Driving Firm Pony AI&#8217;s US IPO: Report</a></li>
</ul>
Image via Quantum-Si

Equities

Contracts

Quantum-Si Shares Slip After Next-Gen Proteomics Platforms Are Unveiled

Barclays analyst Saket Kalia maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $200 to $220.

Barclays Maintains Overweight on Zscaler, Raises Price Target to $220

RBC Capital analyst Deane Dray reiterates Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform and maintains $115 price target.

RBC Capital Reiterates Outperform on Pentair, Maintains $115 Price Target

JOHN FISHER, Vice President at Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), reported an insider sell on November 20, according to a new SEC filing. 
What Happened: FISHER opted to sell 7,817 shares of Federated Hermes, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001056288/000095017024129240//Archives/edgar/data/1056288/000095017024129240/0000950170-24-129240-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The transaction's total worth stands at $323,336.
In the Thursday's morning session, Federated Hermes's shares are currently trading at $41.42, experiencing a down of 0.0%.
<h3>Discovering Federated Hermes: A Closer Look</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $782.7 billion in managed assets at the end of June 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 50% of Federated's revenue this year, compared with 28%, 12%, and 10%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (64% of AUM), institutional investors (27%), and international clients (9%).
<h3>Federated Hermes's Financial Performance</h3>
Revenue Growth: Federated Hermes's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.44%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a high gross margin of 66.7%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Federated Hermes's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.06.
</li>
</ul>
Debt Management: Federated Hermes's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.41.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 13.11, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 2.08, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 7.75, Federated Hermes could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes Worth Your Attention</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001056288">Check Out The Full List Of Federated Hermes's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Transaction: JOHN FISHER Sells $323K Worth Of Federated Hermes Shares

A substantial insider sell was reported on November 20, by Joseph Thomas Guerrieri JR, SVP at Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>), based on the recent SEC filing.
What Happened: After conducting a thorough analysis, JR sold 3,000 shares of Tanger. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000899715/000089971524000151//Archives/edgar/data/899715/000089971524000151/0000899715-24-000151-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $108,810.
The latest market snapshot at Thursday morning reveals Tanger shares down by 0.0%, trading at $36.43.
<h3>Get to Know Tanger Better</h3>
Tanger Inc is a leading owner and operator of outlet and open-air retail shopping destinations. Tanger's portfolio of 38 outlet centers and one open-air lifestyle center comprises over 15 million square feet well positioned across tourist destinations and vibrant markets in U.S. states and Canada.
<h3>A Deep Dive into Tanger's Financials</h3>
Revenue Growth: Tanger's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 13.34%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a low gross margin of 69.74%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Tanger exhibits below-average bottom-line performance with a current EPS of 0.23.
</li>
</ul>
Debt Management: Tanger's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.66, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 41.87, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 7.8, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 18.87, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000899715">Check Out The Full List Of Tanger's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Tanger Recent Insider Activity

Jian James Huang, EVP at Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>), reported an insider sell on November 20, according to a new SEC filing. 
What Happened: Huang's recent move involves selling 3,017 shares of Adient. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001670541/000167054124000124//Archives/edgar/data/1670541/000167054124000124/0001670541-24-000124-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value is $59,585.
At Thursday morning, Adient shares are down by 0.94%, trading at $18.88.
<h3>Discovering Adient: A Closer Look</h3>
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion and fiscal 2024 is forecast to about $14.6 billion.
<h3>A Deep Dive into Adient's Financials</h3>
Decline in Revenue: Over the 3 months period, Adient faced challenges, resulting in a decline of approximately -4.48% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 6.88%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Adient's EPS reflects a decline, falling below the industry average with a current EPS of 0.918605.
</li>
</ul>
Debt Management: Adient's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.13, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Adient's current Price to Earnings (P/E) ratio of 95.3 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.12 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Adient's EV/EBITDA ratio, lower than industry averages at 4.69, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001670541">Check Out The Full List Of Adient's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADNT

Insider Transaction: Jian James Huang Sells $59K Worth Of Adient Shares

Theodore Zierden III, Vice President at Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), reported an insider sell on November 20, according to a new SEC filing. 
What Happened: III's decision to sell 2,478 shares of Federated Hermes was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001056288/000095017024129271//Archives/edgar/data/1056288/000095017024129271/0000950170-24-129271-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $102,621.
During Thursday's morning session, Federated Hermes shares down by 0.0%, currently priced at $41.42.
<h3>About Federated Hermes</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $782.7 billion in managed assets at the end of June 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 50% of Federated's revenue this year, compared with 28%, 12%, and 10%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (64% of AUM), institutional investors (27%), and international clients (9%).
<h3>Federated Hermes's Financial Performance</h3>
Revenue Growth: Federated Hermes's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.44%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 66.7%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Federated Hermes's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.06.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 13.11 is lower than the industry average, implying a discounted valuation for Federated Hermes's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 2.08 is lower than the industry average, implying a discounted valuation for Federated Hermes's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Federated Hermes's EV/EBITDA ratio, lower than industry averages at 7.75, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001056288">Check Out The Full List Of Federated Hermes's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Vice President Of Federated Hermes Makes $102K Sale

A notable insider purchase on November 20, was reported by Ralph Alvarez, Board Member at Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), based on the most recent SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947824000260//Archives/edgar/data/59478/000005947824000260/0000059478-24-000260-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Alvarez purchased 318 shares of Eli Lilly, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $231,749.
The latest update on Thursday morning shows Eli Lilly shares down by 1.52%, trading at $741.94.
<h3>Unveiling the Story Behind Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Breaking Down Eli Lilly's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 20.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 81.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 2.19, Eli Lilly faces challenges in effectively managing its debt levels, indicating potential financial strain.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 81.19 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 16.67 is above industry norms, reflecting an elevated valuation for Eli Lilly's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Eli Lilly's EV/EBITDA ratio of 59.36 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000059478">Check Out The Full List Of Eli Lilly's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Ralph Alvarez Boosts Confidence With $231K Purchase Of Eli Lilly Stock

Peter Germain, EVP at Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), disclosed an insider sell on November 20, according to a recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001056288/000095017024129287//Archives/edgar/data/1056288/000095017024129287/0000950170-24-129287-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday outlined that Germain executed a sale of 4,922 shares of Federated Hermes with a total value of $203,580.
In the Thursday's morning session, Federated Hermes's shares are currently trading at $41.26, experiencing a down of 0.38%.
<h3>Delving into Federated Hermes's Background</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $782.7 billion in managed assets at the end of June 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 50% of Federated's revenue this year, compared with 28%, 12%, and 10%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (64% of AUM), institutional investors (27%), and international clients (9%).
<h3>Financial Insights: Federated Hermes</h3>
Positive Revenue Trend: Examining Federated Hermes's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.44% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 66.7%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Federated Hermes exhibits below-average bottom-line performance with a current EPS of 1.06.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Federated Hermes's P/E ratio of 13.11 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.08 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Federated Hermes's EV/EBITDA ratio at 7.75 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001056288">Check Out The Full List Of Federated Hermes's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP At Federated Hermes Sells $203K Of Stock

Making a noteworthy insider sell on November 20, Richard Novak, Principal Accounting Officer at Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), is reported in the latest SEC filing.
What Happened: Novak's recent move involves selling 1,363 shares of Federated Hermes. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001056288/000095017024129289//Archives/edgar/data/1056288/000095017024129289/0000950170-24-129289-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value is $56,517.
During Thursday's morning session, Federated Hermes shares down by 0.0%, currently priced at $41.42.
<h3>About Federated Hermes</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $782.7 billion in managed assets at the end of June 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 50% of Federated's revenue this year, compared with 28%, 12%, and 10%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (64% of AUM), institutional investors (27%), and international clients (9%).
<h3>Federated Hermes's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Federated Hermes showcased positive performance, achieving a revenue growth rate of 1.44% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 66.7%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Federated Hermes's EPS is below the industry average. The company faced challenges with a current EPS of 1.06. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Federated Hermes's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 13.11, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 2.08, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 7.75, Federated Hermes's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001056288">Check Out The Full List Of Federated Hermes's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Principal Accounting Officer Of Federated Hermes Makes $56K Sale

On November 20, a recent SEC filing unveiled that Anwar Saker Nusseibeh, CEO at Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) made an insider sell.
What Happened: After conducting a thorough analysis, Nusseibeh sold 4,454 shares of Federated Hermes. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001056288/000095017024129290//Archives/edgar/data/1056288/000095017024129290/0000950170-24-129290-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $184,300.
In the Thursday's morning session, Federated Hermes's shares are currently trading at $41.42, experiencing a down of 0.0%.
<h3>Discovering Federated Hermes: A Closer Look</h3>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $782.7 billion in managed assets at the end of June 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 50% of Federated's revenue this year, compared with 28%, 12%, and 10%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (64% of AUM), institutional investors (27%), and international clients (9%).
<h3>Federated Hermes: Financial Performance Dissected</h3>
Revenue Growth: Federated Hermes's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.44%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 66.7%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Federated Hermes's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.06.
</li>
</ul>
Debt Management: Federated Hermes's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Federated Hermes's P/E ratio of 13.11 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.08 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 7.75, Federated Hermes's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001056288">Check Out The Full List Of Federated Hermes's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Federated Hermes CEO Sold $184K In Company Stock

Cadrenal Therapeutics, Inc. (CVKD) has issued an update. Cadrenal Therapeutics has announced a partnership with Abbott to propel its key trial for ...

Cadrenal Therapeutics Partners with Abbott on Cardiac Trial

Abbott to collaborate with Cadrenal on anticoagulant tecarfarin

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the second quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -15 cents. This was below the analyst estimate for EPS of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cvkd-stock-earnings-cadrenal-therapeutics-for-q2-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. Cadrenal Therapeutics, Inc. has refreshed its investor presentation with detail...

Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully...

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin

Cadrenal Therapeutics (CVKD) has raised gross proceeds of approximately $5.1M through its at-the-market facility, selling an aggregate of 391,243 s...

Cadrenal Therapeutics raises $5.1M via at-the-market facility

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q3 earnings. Here is a breakdown of the information Cadrenal Therapeutics, Inc. presented ...

Cadrenal Therapeutics Advances Tecarfarin Development

Cadrenal Therapeutics reports Q3 results

16:09 EST Cadrenal Therapeutics (CVKD) files to sell 590K shares of common stock for holders Published first on TheFly – the ultimate source for re...

Cadrenal Therapeutics files to sell 590K shares of common stock for holders

Cadrenal Therapeutics files to sell 590,001 shares of common stock for holders

Press Releases

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Offerings

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Comments

Cadrenal Therapeutics

Cadrenal Therapeutics (CVKD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga